- Home
- IRWD vs TVRD Comparison
IRWD vs TVRD Comparison
Compare IRWD & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRWD
- TVRD
- Stock Information
- Founded
- IRWD 1998
- TVRD 2017
- Country
- IRWD United States
- TVRD United States
- Employees
- IRWD N/A
- TVRD N/A
- Industry
- IRWD Biotechnology: Pharmaceutical Preparations
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- IRWD Health Care
- TVRD Health Care
- Exchange
- IRWD Nasdaq
- TVRD Nasdaq
- Market Cap
- IRWD 251.8M
- TVRD 246.5M
- IPO Year
- IRWD 2010
- TVRD N/A
- Fundamental
- Price
- IRWD $3.11
- TVRD $4.13
- Analyst Decision
- IRWD Buy
- TVRD Buy
- Analyst Count
- IRWD 5
- TVRD 7
- Target Price
- IRWD $5.34
- TVRD $51.67
- AVG Volume (30 Days)
- IRWD 3.2M
- TVRD 242.3K
- Earning Date
- IRWD 11-10-2025
- TVRD 11-13-2025
- Dividend Yield
- IRWD N/A
- TVRD N/A
- EPS Growth
- IRWD N/A
- TVRD N/A
- EPS
- IRWD 0.18
- TVRD N/A
- Revenue
- IRWD $338,987,000.00
- TVRD N/A
- Revenue This Year
- IRWD N/A
- TVRD N/A
- Revenue Next Year
- IRWD N/A
- TVRD N/A
- P/E Ratio
- IRWD $17.56
- TVRD N/A
- Revenue Growth
- IRWD N/A
- TVRD N/A
- 52 Week Low
- IRWD $0.53
- TVRD $3.85
- 52 Week High
- IRWD $5.13
- TVRD $43.65
- Technical
- Relative Strength Index (RSI)
- IRWD 74.04
- TVRD 21.32
- Support Level
- IRWD $1.88
- TVRD $3.87
- Resistance Level
- IRWD $3.47
- TVRD $4.45
- Average True Range (ATR)
- IRWD 0.33
- TVRD 0.31
- MACD
- IRWD 0.12
- TVRD 1.01
- Stochastic Oscillator
- IRWD 79.56
- TVRD 25.22
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.